Biomarker-based investigations, including IL-6, C-reactive protein, TNF-α, and adipokines, may provide mechanistic insights into the interplay between cutaneous inflammation and systemic metabolic dysfunction, as well as identify shared inflammatory pathways between dermatologic and metabolic diseases. This evidence concerns the gene IL6 and metabolic disease.